Egypt’s Eva Pharma begins producing COVID-19 drug Remdesivir – ZAWYA

Egypt’s Eva Pharma begins producing COVID-19 drug Remdesivir – ZAWYA

Egypt's Eva Pharma begins producing COVID-19 drug Remdesivir Egypt's Eva Pharma begins producing COVID-19 drug Remdesivir | ZAWYA MENA Edition HomeBusinessArticleEgypt's Eva Pharma begins producing COVID-19 drug Remdesivir Remdesivir is indicated for moderate to severe cases of COVID-19 for patients in intensive care who require oxygen, while Favipiravir is indicated for mild to moderate cases    Two ampules of Ebola drug Remdesivir are pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany, April 8, 2020, as the spread of coronavirus disease (COVID-19) continues. Ulrich Perrey/Pool via REUTERSCAIRO  - Egypt's Eva Pharma said on Thursday it had begun producing Remdesivir and Favipiravir, two drugs used in the treatment of patients with COVID-19.Remdesivir is indicated for moderate to severe cases of COVID-19 for patients in intensive care who require oxygen, while Favipiravir is indicated for mild to moderate cases.Eva Pharma, a generic drugmaker established in 1997, said earlier this month it had received a licence from Gilead Sciences Inc to make Remdesivir in Egypt and distribute it in 127 countries.Remdesivir is indicated for moderate to severe cases of COVID-19 for patients in intensive care who require oxygen, while Favipiravir is indicated for mild to moderate cases.CAIRO  -